Drug Sensitivity Correlation Between Patient-Derived Organoid Model and Clinical Response in NSCLC Patients

Inclusion Criteria:

* Aged 18 years old or more;
* Late stage NSCLC patients, with tumor invasion confirmed by histopathology analysis. Metastasis of axillary lymph nodes and other region lymph nodes are confirmed with histopathologic or cytopathologic analysis;
* Accessible to biopsy and/or surgery sample of metastasis and/or primitive tumor;
* No clinical evidence of other malignancy, unstable complication or uncontrolled infection;
* Life expectancy \> 12 months.
* Informed and signed consent by the patient.

Exclusion Criteria:

* Not accessible to biopsy and/or surgery sample;
* Patient already enrolled in another clinical trial with another first line of chemotherapy;
* Unmeasurable locally advanced (incurable) or metastatic lesion(s), according to RECIST 1.1 criteria;
* Women who are pregnant, plan to become pregnant or are lactating during the study;
* Elevation of carcinoembryonic antigen (CEA) observed without distal metastases found;
* Have some kind of contraindications for chemotherapy and targeted therapy: cardiovascular and cerebrovascular diseases; liver and kidney function deficiency; hematological system diseases; clinician consider the patients are not suitable for chemotherapies or target therapies;
* Have other malignant tumor previously;
* Have surgical contraindications: anesthesia taboo; surgery unresectable extensive lesions;
* State of health can't finish the study;
* Patient already enrolled in another clinical trial with another anti-cancer therapy or plan to participate in other clinical study.
* No self-determination or refuse to participant.
* With unlisted exclusion criteria but are considered not suitable for the clinical study by researchers.